These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 9541161)
1. Possible dose-response relationship for risperidone in obsessive-compulsive disorder. Baker RW J Clin Psychiatry; 1998 Mar; 59(3):134. PubMed ID: 9541161 [No Abstract] [Full Text] [Related]
2. Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder may be dose-dependent. Ramasubbu R Arch Gen Psychiatry; 2002 May; 59(5):472; author reply 472-3. PubMed ID: 11982460 [No Abstract] [Full Text] [Related]
3. Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology. Agid O; Lerer B J Clin Psychiatry; 1999 Jan; 60(1):55-6. PubMed ID: 10074882 [No Abstract] [Full Text] [Related]
4. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469 [TBL] [Abstract][Full Text] [Related]
5. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. Stein DJ; Bouwer C; Hawkridge S; Emsley RA J Clin Psychiatry; 1997 Mar; 58(3):119-22. PubMed ID: 9108814 [TBL] [Abstract][Full Text] [Related]
10. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523 [TBL] [Abstract][Full Text] [Related]
11. A case of social phobia with obsessive-compulsive symptoms improved by paroxetine in combination with risperidone. Yamauchi K; Ohta K; Taniguchi T; Ohmori T Gen Hosp Psychiatry; 2004; 26(3):242-3. PubMed ID: 15121355 [No Abstract] [Full Text] [Related]
12. Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia. Dwivedi S; Pavuluri M; Heidenreich J; Wright T J Child Adolesc Psychopharmacol; 2002; 12(1):69-70. PubMed ID: 12014598 [No Abstract] [Full Text] [Related]
13. A case report of risperidone-induced obsessive-compulsive symptoms. Alzaid K; Jones BD J Clin Psychopharmacol; 1997 Feb; 17(1):58-9. PubMed ID: 9004062 [No Abstract] [Full Text] [Related]
14. Augmenting obsessive-compulsive disorder treatment: from brain to mind. Ressler KJ; Rothbaum BO JAMA Psychiatry; 2013 Nov; 70(11):1129-31. PubMed ID: 24026506 [No Abstract] [Full Text] [Related]
15. Augmenting SRIs for Obsessive-Compulsive Disorder: Patient Preference for Risperidone Does Not Limit Effectiveness of Exposure and Ritual Prevention. Wheaton MG; Carpenter JK; Kalanthroff E; Foa EB; Simpson HB Psychother Psychosom; 2016; 85(5):314-6. PubMed ID: 27513584 [TBL] [Abstract][Full Text] [Related]
16. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567 [TBL] [Abstract][Full Text] [Related]
17. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Selvi Y; Atli A; Aydin A; Besiroglu L; Ozdemir P; Ozdemir O Hum Psychopharmacol; 2011 Jan; 26(1):51-7. PubMed ID: 21308781 [TBL] [Abstract][Full Text] [Related]